Funds holding TRANSCODE THERAPEUTICS INC
ISIN US89357L5012 · United States
- Fund holders
- 4
- Of which ETFs
- 0 4 other funds
- Value held
- 93K $
- Share of capital
- 0.1 % of 16.9M shares on Aug 10, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 8,492 | 43.6K $ | 0.00 % | 0.05 % | as of May 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 6,545 | 40.6K $ | 0.04 % | as of Jun 30, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 1,180 | 6.1K $ | 0.01 % | as of May 31, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 510 | 2.6K $ | 0.00 % | as of May 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 4 | 0 | 16,727 | +19.3 % |
| 2026Q2 | 4 | -1 | 14,018 | +22.1 % |
| 2026Q1 | 5 | 0 | 11,481 | +3.9 % |
| 2025Q4 | 5 | +1 | 11,046 | +1,851.6 % |
| 2025Q3 | 4 | 566 |
Institutional managers
5 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 12,740 | 109.7K $ | as of Mar 31, 2026 |
| UBS Group AG | 8,295 | 71.4K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 228 | 2K $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 55 | 474 $ | as of Mar 31, 2026 |
| SBI Securities Co., Ltd. | 12 | 103 $ | as of Mar 31, 2026 |
Declared shareholders of TRANSCODE THERAPEUTICS INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| DEFJ, LLC and 1 other | 83.90 % | 14,134,481 | as of Aug 3, 2026 · SCHEDULE 13D |
| Unleash Immuno Oncolytics, Inc. | 9.94 % | 300,000 | as of Jul 23, 2026 · SCHEDULE 13G |
| Elena Rosa Braci | 6.17 % | 186,236 | as of Jul 23, 2026 · SCHEDULE 13G |
| Daniel Eduardo Katzman | 5.16 % | 155,611 | as of Jul 23, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding TRANSCODE THERAPEUTICS INC". https://titelia.com/en/stocks/transcode-therapeutics-inc-US89357L5012